144 related articles for article (PubMed ID: 29359381)
1. Inappropriate medication use and polypharmacy in end-stage cancer patients: Isn't it the family doctor's role to de-prescribe much earlier?
Garfinkel D; Ilin N; Waller A; Torkan-Zilberstein A; Zilberstein N; Gueta I
Int J Clin Pract; 2018 Apr; 72(4):e13061. PubMed ID: 29359381
[TBL] [Abstract][Full Text] [Related]
2. How general practitioners would deprescribe in frail oldest-old with polypharmacy - the LESS study.
Mantelli S; Jungo KT; Rozsnyai Z; Reeve E; Luymes CH; Poortvliet RKE; Chiolero A; Rodondi N; Gussekloo J; Streit S
BMC Fam Pract; 2018 Oct; 19(1):169. PubMed ID: 30314468
[TBL] [Abstract][Full Text] [Related]
3. A Study of Medication Use of Cancer and Non-Cancer Patients in Home Hospice Care in Singapore: A Retrospective Study from 2011 to 2015.
Wenedy A; Lim YQ; Lin Ronggui CK; Koh GCH; Chong PH; Chew LST
J Palliat Med; 2019 Oct; 22(10):1243-1251. PubMed ID: 31066621
[No Abstract] [Full Text] [Related]
4. Changes in preventive medical therapies and CV risk factors after CT angiography.
Cheezum MK; Hulten EA; Smith RM; Taylor AJ; Kircher J; Surry L; York M; Villines TC
JACC Cardiovasc Imaging; 2013 May; 6(5):574-81. PubMed ID: 23582355
[TBL] [Abstract][Full Text] [Related]
5. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
7. Use of cardiovascular medicines in newly treated type 2 diabetes patients: A retrospective cohort study in general practice.
Grimes RT; Ensor J; Bennett K; Henman MC
Prim Care Diabetes; 2016 Aug; 10(4):237-43. PubMed ID: 26654852
[TBL] [Abstract][Full Text] [Related]
8. Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer.
Park JW; Roh JL; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
J Cancer Res Clin Oncol; 2016 May; 142(5):1031-40. PubMed ID: 26744323
[TBL] [Abstract][Full Text] [Related]
9. The development of polypharmacy. A longitudinal study.
Veehof L; Stewart R; Haaijer-Ruskamp F; Jong BM
Fam Pract; 2000 Jun; 17(3):261-7. PubMed ID: 10846147
[TBL] [Abstract][Full Text] [Related]
10. Polypharmacy and drug omissions across hospices in Northern Ireland.
Lundy E; McMullan D; McShane P; Williams M; Watson M; White C
J Palliat Med; 2013 Nov; 16(11):1446-9. PubMed ID: 24131309
[TBL] [Abstract][Full Text] [Related]
11. Polypharmacy patterns in the last year of life in patients with dementia.
Denholm R; Morris R; Payne R
Eur J Clin Pharmacol; 2019 Nov; 75(11):1583-1591. PubMed ID: 31346649
[TBL] [Abstract][Full Text] [Related]
12. The Burden of Polypharmacy in Patients Near the End of Life.
McNeil MJ; Kamal AH; Kutner JS; Ritchie CS; Abernethy AP
J Pain Symptom Manage; 2016 Feb; 51(2):178-83.e2. PubMed ID: 26432571
[TBL] [Abstract][Full Text] [Related]
13. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
14. Potentially inappropriate prescribing (IP) for elderly medical inpatients in Taiwan: a hospital-based study.
Liu CL; Peng LN; Chen YT; Lin MH; Liu LK; Chen LK
Arch Gerontol Geriatr; 2012; 55(1):148-51. PubMed ID: 21820189
[TBL] [Abstract][Full Text] [Related]
15. Polypharmacy and medication errors on admission to palliative care.
Grądalski T
Pol Arch Intern Med; 2019 Oct; 129(10):659-666. PubMed ID: 31502585
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
[TBL] [Abstract][Full Text] [Related]
17. Why do family doctors prescribe potentially inappropriate medication to elderly patients?
Voigt K; Gottschall M; Köberlein-Neu J; Schübel J; Quint N; Bergmann A
BMC Fam Pract; 2016 Jul; 17():93. PubMed ID: 27449802
[TBL] [Abstract][Full Text] [Related]
18. Choosing Wisely? Measuring the Burden of Medications in Older Adults near the End of Life: Nationwide, Longitudinal Cohort Study.
Morin L; Vetrano DL; Rizzuto D; Calderón-Larrañaga A; Fastbom J; Johnell K
Am J Med; 2017 Aug; 130(8):927-936.e9. PubMed ID: 28454668
[TBL] [Abstract][Full Text] [Related]
19. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy.
Garfinkel D; Mangin D
Arch Intern Med; 2010 Oct; 170(18):1648-54. PubMed ID: 20937924
[TBL] [Abstract][Full Text] [Related]
20. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
